Search the GHTC website

Global health R&D delivers for South Carolina

US government investment in global health R&D has delivered

$3.7 million
to South Carolina research institutions
South Carolina's top USG-funded global health R&D institutions

South Carolina's top USG-funded global health R&D institutions

University of South Carolina at Columbia
$1.6 million
Clemson University
$1.4 million
Medical University of South Carolina
$723 thousand
South Carolina industry in global health R&D

South Carolina industry in global health R&D

Location(s): Ladson
Charles River Laboratories
Location(s): Charleston
Coastal Carolina Research Center
Location(s): Mount Pleasant

South Carolina's top areas of global health R&D by USG funding

Salmonella infections
Neglected tropical diseases
Global health R&D at work in South Carolina

Clemson University researchers are seeking new treatments for sleeping sickness, a dis-ease that threatens millions of people in sub-Saharan Africa. Infection begins with the bite of a tsetse fly carrying a deadly parasite. Because the parasite also infects and kills livestock, it is a major obstacle to economic development in the region. Existing treatments are difficult to administer and can be toxic, even fatal. The scientists are studying metabolic targets that could lead to a cure. They aim to cut off the parasites from their source of energy: sugar. Molecules that show promise will be evaluated as potential drugs. If successful, the work could lead to treatments for other parasitic infections, such as Chagas disease and leishmaniasis.

  • Methodology
  • USG global health R&D investment to state research institutions/Top USG-funded global health R&D institutions: Authors' analysis of USG investment data from the G-FINDER survey, including funding for R&D for neglected diseases from 2007–2015 and for Ebola and select viral hemorrhagic fevers from 2014–2015. Reflects USG funding received by entities in state including academic and research institutions, product development partnerships, other nonprofits, select corporations, and government research institutions, as well as self-funding or other federal agency transfers received by federal agencies located in state; but excludes pharmaceutical industry data which is aggregated and anonymized in the survey for confidentiality purposes. See methodology for additional details.
  • Case study photo: PATH/Georgina Goodwin